Treatment of systemic mast cell disease: beyond interferon.
Tefferi
Ayalew
A
D000963:Antimetabolites / Q000627:therapeutic use*; D001549:Benzamides; D017338:Cladribine / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000627:therapeutic use; D034721:Mastocytosis, Systemic / Q000188:drug therapy* / Q000235:genetics; D015514:Oncogene Proteins, Fusion; D010865:Pilot Projects; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics; D039221:mRNA Cleavage and Polyadenylation Factors / Q000235:genetics
D000963:Antimetabolites; D001549:Benzamides; D016898:Interferon-alpha; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D039221:mRNA Cleavage and Polyadenylation Factors; D017338:Cladribine; D000068877:Imatinib Mesylate; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha